Target intelligence / Profile preview

Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B)

Target
TNFRSF11B
Molecular classification
Receptor, Decoy receptor, Tumor necrosis factor receptor superfamily
01

Overview

Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), widely known as osteoprotegerin (OPG), is a secreted glycoprotein that plays a pivotal role in bone metabolism and vascular homeostasis. It acts as a soluble decoy receptor for receptor activator of nuclear factor kappa-B ligand (RANKL), thereby preventing RANKL from binding to its signaling receptor RANK on osteoclast precursors. This interaction serves as a critical physiological brake on osteoclastogenesis, inhibiting the differentiation, activation, and survival of bone-resorbing osteoclasts. Beyond bone remodeling, TNFRSF11B also binds to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), protecting cells from TRAIL-mediated apoptosis, which has complex implications in cancer cell survival and metastasis.

In clinical development, recombinant OPG constructs such as AMGN-0007 were evaluated for treating osteoporosis, multiple myeloma, and breast cancer-related bone metastases. However, safety concerns regarding the potential development of neutralizing antibodies against endogenous OPG—which could trigger severe, unchecked bone resorption—led to the discontinuation of recombinant OPG therapies in favor of RANKL-targeted monoclonal antibodies like denosumab. Additionally, bisphosphonates like zoledronic acid indirectly modulate bone density by upregulating endogenous TNFRSF11B expression. TNFRSF11B remains a highly studied biomarker and therapeutic node in metabolic bone diseases, vascular calcification, and oncology.

Other names
OsteoprotegerinOPGOsteoclastogenesis inhibitory factorOCIFTumor necrosis factor receptor superfamily member 11BTNF receptor superfamily member 11bTR1PDB5
02

Mechanism of action

Recombinant OPG (AMGN-0007) acts as a decoy receptor that binds to RANKL (TNFSF11), preventing its interaction with RANK and thereby inhibiting osteoclastogenesis and bone resorption. Dulanermin binds to TNFRSF11B as a decoy receptor, which can neutralize its pro-apoptotic activity. Bisphosphonates (zoledronic acid, pamidronate, risedronate) increase the expression and secretion of endogenous TNFRSF11B by osteoblasts.

03

Biological functions

Bone remodelingBone homeostasisNegative regulation of osteoclastogenesisApoptosis regulationPrevention of arterial calcificationCell survivalSignal transduction
04

Disease associations

OsteoporosisPaget's disease of boneBone metastasisMultiple myelomaCardiovascular diseaseCancer
05

Safety considerations

Risk of inducing neutralizing anti-drug antibodies (ADAs) against endogenous OPG, potentially causing severe osteoporosisHypocalcemiaPotential promotion of tumor survival by neutralizing TRAIL-induced apoptosisAltered vascular calcification
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Serum osteoprotegerin (OPG) levelUrinary N-telopeptide of collagen (NTX)Serum C-telopeptide of type I collagen (CTX-I)Serum procollagen type 1 N-terminal propeptide (P1NP)Bone mineral density (BMD)

Beyond the preview

Go deeper on Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call